A first-in-patient, multi-ascending dose trial of PRS-343 for the treatment of HER-2 positive solid tumors

Trial Profile

A first-in-patient, multi-ascending dose trial of PRS-343 for the treatment of HER-2 positive solid tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Oct 2017

At a glance

  • Drugs PRS 343 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Pieris Pharmaceuticals
  • Most Recent Events

    • 02 Oct 2017 According to a Pieris Pharmaceuticals, Inc. media release, the first patient has been dosed in this trial.
    • 02 Oct 2017 According to a Pieris Pharmaceuticals, Inc. media release, status changed from planning to recruiting.
    • 09 Aug 2017 According to a Pieris Pharmaceuticals media release, the company expects to to dose first patient in this trial very soon.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top